Rucaparib: "All patients in the rucaparib arm and 182/189 (96.3%) patients in the placebo arm experienced ≥1 TEAE"; Ovarian cancer (Clovis Oncology) - Sep 19, 2020 - ESMO 2020: "Grade ≥3 TEAEs were reported by 231/372 (62.1%) patients in the rucaparib arm and 31/189 (16.4%) patients in the placebo arm, Grade 4 TEAEs were reported by 28/372 (7.5%) and 2/189 patients (1.1%) in the rucaparib and placebo arms, respectively. The most frequent grade 4 TEAEs in the rucaparib arm were neutropenia/ decreased neutrophils and thrombocytopenia/decreased platelets (7/372 patients [1.9%] each)"
P3 data • Oncology • Ovarian Cancer
|